Peptidomics-Based Research Service

• • Food-Derived Functional Bioactive Peptides Discovery Service

  Bioactive peptides are short amino acid sequences with specific physiological functions that are released from parent proteins through enzymatic hydrolysis or gastrointestinal digestion. Found abundantly in food sources such as milk, soy, meat, fish, and cereals, these peptides have attracted growing attention for their potential applications in health promotion, functional food development, and preventive medicine.

• • Pharmacopeptidomics Research Service

  Pharmacopeptidomics is an emerging discipline at the intersection of pharmacology and peptide science, focusing on the systematic investigation of endogenous peptides in the context of drug action and therapeutic modulation. By integrating advanced mass spectrometry-based peptidomics with pharmacodynamic and pharmacokinetic analyses...

• • Peptide Drug Quality Control Service

  Peptide-based drugs have become an increasingly significant class of therapeutics due to their high specificity and low toxicity. With advances in peptide drug development, there is a growing need for stringent quality control processes to ensure the safety, efficacy, and consistency of peptide-based therapies. The complex nature of peptides, which includes structural variations, post-translational modifications (PTMs), and issues such as aggregation and stability, requires...

• • Peptidomics-Based Molecular Glue Mechanism Research Service

  Molecular glues are small molecules that regulate target protein functions by promoting protein-protein interactions. They have shown significant potential in targeting otherwise “undruggable” proteins, inducing protein degradation, and modulating protein complex assembly. Unlike inhibitors or PROTACs, molecular glues do not require a linker between the E3 ligase and the target protein. Instead, they exert their effects by stabilizing or inducing natural or novel protein interactions, achieving target......

• • Peptidomics-Based Drug Target Research Service

  The identification and validation of drug targets are fundamental to the development of effective therapeutics. Traditional target discovery approaches, such as genomics, transcriptomics, and proteomics, provide valuable information about potential targets. However, these methods often fail to capture the full complexity of proteolytic regulation, post-translational processing, and functional peptide signaling.

• • Peptidomics-Based PROTAC Research Service

  PROTAC (Proteolysis Targeting Chimera) is a class of small molecules that induce selective degradation of target proteins via the ubiquitin-proteasome system (UPS). By linking target protein ligands with E3 ubiquitin ligase ligands, PROTACs promote the degradation of specific proteins, enabling "targeted removal" rather than traditional "functional inhibition." In understanding PROTAC mechanisms and validating targets, peptidomics offers a critical complement. This high-throughput approach identifies ......

• • Peptidomics-Based Drug Side Effects Research Service

  The development of new drugs is an intricate process that requires not only the evaluation of therapeutic efficacy but also a thorough understanding of potential side effects that could compromise patient safety. Side effects may arise from various factors, including unintended interactions with non-target proteins, alterations in cellular signaling pathways, or disturbances in homeostasis. These adverse effects can lead to reduced drug effectiveness, unwanted toxicity, and, ultimately, clinical failure.

• • Peptidomics-Based Drug Off-Target Effects Research Service

  Off-target effects are a major concern in drug development, often leading to reduced therapeutic efficacy, unexpected toxicity, and clinical failure. These unintended biological interactions occur when a drug interacts with proteins, receptors, or signaling pathways other than its intended target. Understanding and mitigating off-target effects is crucial for improving drug safety, optimizing dosing strategies, and meeting regulatory expectations.

• • New Polypeptide Prodrugs Development Service

  Polypeptide prodrugs represent a specialized class of therapeutic compounds in which bioactive drug molecules are chemically conjugated with polypeptides to enhance their pharmacokinetic behavior, biological stability, and tissue-specific delivery. This design enables controlled activation of the drug in vivo, improving therapeutic efficacy while reducing systemic toxicity and dosing frequency.

• • Peptide Variants Characterization Service

  Peptide Variants Characterization Service is designed to identify, characterize and annotate various forms of peptide variants, and analyze their origins, structural characteristics, expression differences and potential functions. MtoZ Biolabs offers Peptide Variant Characterization Service aimed at the systematic identification and analysis of peptide variants arising from sequence mutations, splice isoforms, or post-translational modifications.